Article(id=1329869408509473218, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.01.009, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1666195200000, receivedDateStr=2022-10-20, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995174767, onlineDateStr=2026-11-18, pubDate=1673280000000, pubDateStr=2023-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995174767, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995174767, creator=13701087609, updateTime=1794995174767, updator=13701087609, issue=Issue{id=1329869401546928487, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='1', pageStart='1', pageEnd='100', issueExtLink='null', onlineDate='null', pubDate='1673280000000', pubDateStr='2023-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995173107, creator='13701087609', updateTime=1794995764620, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329871882981060993, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329871882981060994, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=51, endPage=58, ext={EN=ArticleExt(id=1329869408765325763, articleId=1329869408509473218, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To estimate the potential health benefits of pembrolizumab for the second-line esophageal squamous cell carcinoma patients with programmed death-ligand 1 positive [combined positive score (CPS)≥10] in China from 2021 to 2025, in order to provide reference for scientific evaluation of clinical benefits of innovative antitumor drugs and effective allocation of health resources.

Methods

A patient flow calculation model and a partitioned survival model were built to calculate the number of patients with second-line esophageal squamous cell carcinoma who might be treated with pembrolizumab from 2021 to 2025. A partitioned survival model was established to estimate the incremental benefits of life year (LY) and quality-adjusted life years (QALYs) gained of an average patient using pembrolizumab compared with regular chemotherapies. The total potential gains in LY and QALYs of the second-line esophageal squamous cell carcinoma patients in China from 2021 to 2025 was calculated by discounting at 5% annually.

Results

In the next 5 years, a total of 43 439 patients could benefit from pembrolizumab. The average lifetime LY and QALYs increments per patient with pembrolizumab are 1.603 and 1.442, respectively. The total increments of LY and QALYs in 5 years gained by the introduction of pembrolizumab were 63 026 and 56 696, respectively.

Conclusions

Programmed death-1 inhibitor is expected to bring considerable survival and quality-of-life benefits for patients with esophageal squamous cell carcinoma in China.

, authors=Jiahua LENG1, 2, Ziyi LIN3, Jianwei XUAN3, *, authorsList=Jiahua LENG, Ziyi LIN, Jianwei XUAN, authorCompany=null, correspAuthors=Jianwei XUAN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869409021178308, articleId=1329869408509473218, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=PD-1抑制剂免疫治疗对中国食管鳞癌患者的潜在健康产出探索, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

测算在2021年至2025年,对于我国程序性死亡受体配体1表达阳性(综合阳性评分≥10)的食管鳞癌患者二线治疗,帕博利珠单抗带来的潜在健康产出获益,以期为科学评估创新抗肿瘤药品临床获益,并有效配置卫生资源提供决策参考。

方法

建立流行病学测算模型,用于计算2021年至2025年可能使用帕博利珠单抗治疗的食管鳞癌患者二线治疗人数。再建立分区生存模型,预估平均1例患者使用帕博利珠单抗治疗对比常规化疗的生命年(life year,LY)和质量调整生命年(quality-adjusted life years,QALYs)增量获益。以5%年利率进行贴现,计算未来5年我国食管鳞癌患者二线治疗的总体潜在获益。

结果

预测未来5年,我国可能使用帕博利珠单抗的获益目标患者共43 439例,平均每例患者终身的LY和QALYs增量分别为1.603和1.442。帕博利珠单抗的引入给我国食管鳞癌患者二线治疗带来的5年总增量LY和QALYs,净现值分别为63 026 LY和56 696 QALYs。

结论

程序性死亡受体1抑制剂有望为中国食管鳞癌患者带来显著的生存和生命质量获益。

, authors=冷家骅1, 2, 林子义3, 宣建伟3, *, authorsList=冷家骅, 林子义, 宣建伟, authorCompany=null, correspAuthors=宣建伟, authorNote=

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

, correspAuthorsNote=
宣建伟,教授,研究方向:卫生政策、卫生经济学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=7VEKYfjusZe/TX6e2Wollw==, magXml=2u/lWfKAfevGfy3YwlJrUA==, pdfUrl=null, pdf=TjJNP98hjP/VnU7IMNEt3g==, pdfFileSize=1891810, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=1R6NTnp2hnxFC9dtwVxb2Q==, mapNumber=null, fund=null)}, authors=[Author(id=1329869409528689104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869409612575187, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409528689104, language=EN, stringName=Jiahua LENG, firstName=Jiahua, middleName=null, lastName=LENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869409675489748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409528689104, language=CN, stringName=冷家骅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142
2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142, bio={"content":"

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

"}, bioImg=null, bioContent=

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409235087814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=1., ext=[AuthorCompanyExt(id=1329869409247670727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409251865032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142)]), AuthorCompany(id=1329869409381888457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=2., ext=[AuthorCompanyExt(id=1329869409390277066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409398665675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142)])]), Author(id=1329869409738404310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869409813901784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409738404310, language=EN, stringName=Ziyi LIN, firstName=Ziyi, middleName=null, lastName=LIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869409914565081, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409738404310, language=CN, stringName=林子义, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.中山大学药学院医药经济研究所,广东 广州 510006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409453191628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=3., ext=[AuthorCompanyExt(id=1329869409461580237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China), AuthorCompanyExt(id=1329869409465774542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中山大学药学院医药经济研究所,广东 广州 510006)])]), Author(id=1329869409973285339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869410082337245, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409973285339, language=EN, stringName=Jianwei XUAN, firstName=Jianwei, middleName=null, lastName=XUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869410292052446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409973285339, language=CN, stringName=宣建伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.中山大学药学院医药经济研究所,广东 广州 510006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409453191628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=3., ext=[AuthorCompanyExt(id=1329869409461580237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China), AuthorCompanyExt(id=1329869409465774542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中山大学药学院医药经济研究所,广东 广州 510006)])])], keywords=[Keyword(id=1329869410438853087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=EN, orderNo=1, keyword=PD-1 inhibitor), Keyword(id=1329869410501767648, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=EN, orderNo=2, keyword=pembrolizumab), Keyword(id=1329869410577265121, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=EN, orderNo=3, keyword=esophageal squamous cell carcinoma), Keyword(id=1329869410669539810, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=EN, orderNo=4, keyword=quality-adjusted life year), Keyword(id=1329869410736648675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=CN, orderNo=1, keyword=PD-1抑制剂), Keyword(id=1329869410807951844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=CN, orderNo=2, keyword=帕博利珠单抗), Keyword(id=1329869410883449317, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=CN, orderNo=3, keyword=食管鳞癌), Keyword(id=1329869410946363878, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, language=CN, orderNo=4, keyword=质量调整生命年)], refs=[Reference(id=1329869411034444263, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=国家卫生健康委员会. 食管癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192., articleTitle=null, refAbstract=null), Reference(id=1329869411105747432, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang Y, Shi J, Du L, et al. Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: a multicenter cross-sectional study[J]. Thoracic Cancer, 2020, 11(4): 1076-1089., articleTitle=null, refAbstract=null), Reference(id=1329869411177050601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=GBD 2017 Oesophageal Cancer Collaborators. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(6): 582-597., articleTitle=null, refAbstract=null), Reference(id=1329869411252548074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南[M]. 北京: 人民卫生出版社, 2020., articleTitle=null, refAbstract=null), Reference(id=1329869411344822763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Grünberger B, Raderer M, Schmidinger M, et al. Palliative chemotherapy for recurrent and metastatic esophageal cancer[J]. Anticancer Res, 2007, 27(4C): 2705-2714., articleTitle=null, refAbstract=null), Reference(id=1329869411407737324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment[J]. J Thorac Dis, 2014, 6(Suppl 3): S289-S297., articleTitle=null, refAbstract=null), Reference(id=1329869411470651885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药物和卫生技术综合评估中心(国家卫生健康委卫生发展研究中心). 国家药物和卫生技术综合评估中心关于发布心血管病、抗肿瘤、儿童药品临床综合评价技术指南的通知[EB/OL]. (2022-06-29) [2022-08-18]. http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f.shtml., articleTitle=null, refAbstract=null), Reference(id=1329869411533566446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=中国药学会. 中国药物经济学评价指南2020[EB/OL]. (2020-12-03) [2022-08-18]. https://www.cpa.org.cn/index.php?do=info&cid=75553., articleTitle=null, refAbstract=null), Reference(id=1329869411596481007, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen J, Luo S, Qin S, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the Chinese subgroup in KEYNOTE-181[J]. Annals Oncol, 2019, 30: v294., articleTitle=null, refAbstract=null), Reference(id=1329869411688755696, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11., articleTitle=null, refAbstract=null), Reference(id=1329869411755864561, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=雷海科, 廖忠莉, 李小升, 等. 重庆市食管癌患者生存随访调查及预后影响因素研究[J]. 中国癌症杂志, 2020, 30(2): 98-105., articleTitle=null, refAbstract=null), Reference(id=1329869411818779122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review[EB/OL]. (2017-06-02) [2022-08-18]. file:///C:/Users/shenjj/Downloads/TSD19-Partitioned-Survival-Analysis-final-report. pdf, articleTitle=null, refAbstract=null), Reference(id=1329869411885887987, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang J, Chmielowski B, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naïve patients with advanced melanoma in the United States[J]. J Manag Care Spec Pharm, 2017, 23(2): 184-194., articleTitle=null, refAbstract=null), Reference(id=1329869411948802548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Huang M, Lou Y, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States[J]. J Med Econ, 2017, 20(2): 140-150., articleTitle=null, refAbstract=null), Reference(id=1329869412011717109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data[EB/OL]. (2013-03) [2022-08-18]. file:///C:/Users/shenjj/Downloads/TSD14-Survival-analysis. updated-March-2013. v2. pdf, articleTitle=null, refAbstract=null), Reference(id=1329869412087214582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu GG, Wu H, Li M, et al. Chinese time trade-off values for EQ-5D health states[J]. Value Health, 2014, 17(5): 597-604., articleTitle=null, refAbstract=null), Reference(id=1329869412183683575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=夏莉花, 濮晓红, 付尧, 等. 免疫组织化学、荧光原位杂交及RNA原位杂交检测PD-L1的一致性比较[J]. 中华病理学杂志, 2020, 49(11): 1183-1186., articleTitle=null, refAbstract=null), Reference(id=1329869412263375352, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=骆新兰, 罗陆侨, 何娇, 等. 免疫组织化学检测条件对PD-L1(22C3)染色结果的影响[J]. 中华病理学杂志, 2020, 49(11): 1108-1113., articleTitle=null, refAbstract=null), Reference(id=1329869412338872825, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=国家卫生健康委办公厅, 国家中医药局办公室, 中央军委后勤保障部卫生局. 关于印发肿瘤诊疗质量提升行动计划的通知[EB/OL]. (2021-10-15) [2022-08-18]. http://www.nhc.gov.cn/yzygj/s7659/202110/dea7d84638db44e28001fbd7d6c6801a.shtml., articleTitle=null, refAbstract=null), Reference(id=1329869412401787386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=中共中央国务院. “健康中国2030”规划纲要[EB/OL]. (2016-10-25) [2022-08-18]. http://www.gov.cn/xinwen/2016-10/25/content_5124174.htm., articleTitle=null, refAbstract=null), Reference(id=1329869412468896251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Joung KI, Song JH, Suh K, et al. Effect of treatment with the PD-1/PD-L1 inhibitors on key health outcomes of cancer patients[J]. BioDrugs, 2021, 35(1): 61-73., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329869409235087814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=1., ext=[AuthorCompanyExt(id=1329869409247670727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409251865032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142)]), AuthorCompany(id=1329869409381888457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=2., ext=[AuthorCompanyExt(id=1329869409390277066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409398665675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142)]), AuthorCompany(id=1329869409453191628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=3., ext=[AuthorCompanyExt(id=1329869409461580237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China), AuthorCompanyExt(id=1329869409465774542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中山大学药学院医药经济研究所,广东 广州 510006)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.01.009, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.01.009, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.01.009, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.01.009, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1673280000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
PD-1抑制剂免疫治疗对中国食管鳞癌患者的潜在健康产出探索
冷家骅 1, 2 , 林子义 3 , 宣建伟 3, *
世界临床药物 | 研究论文 2023,44(1): 51-58
收起
收藏切换
世界临床药物 |研究论文 2023 , 44 (1) : 51 -58
PD-1抑制剂免疫治疗对中国食管鳞癌患者的潜在健康产出探索
全屏
[Author(id=1329869409528689104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869409612575187, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409528689104, language=EN, stringName=Jiahua LENG, firstName=Jiahua, middleName=null, lastName=LENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869409675489748, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409528689104, language=CN, stringName=冷家骅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142
2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142, bio={"content":"

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

"}, bioImg=null, bioContent=

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409235087814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=1., ext=[AuthorCompanyExt(id=1329869409247670727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409251865032, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409235087814, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142)]), AuthorCompany(id=1329869409381888457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=2., ext=[AuthorCompanyExt(id=1329869409390277066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China), AuthorCompanyExt(id=1329869409398665675, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409381888457, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142)])]), Author(id=1329869409738404310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869409813901784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409738404310, language=EN, stringName=Ziyi LIN, firstName=Ziyi, middleName=null, lastName=LIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869409914565081, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409738404310, language=CN, stringName=林子义, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.中山大学药学院医药经济研究所,广东 广州 510006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409453191628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=3., ext=[AuthorCompanyExt(id=1329869409461580237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China), AuthorCompanyExt(id=1329869409465774542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中山大学药学院医药经济研究所,广东 广州 510006)])]), Author(id=1329869409973285339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869410082337245, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409973285339, language=EN, stringName=Jianwei XUAN, firstName=Jianwei, middleName=null, lastName=XUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869410292052446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, authorId=1329869409973285339, language=CN, stringName=宣建伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.中山大学药学院医药经济研究所,广东 广州 510006, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869409453191628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, xref=3., ext=[AuthorCompanyExt(id=1329869409461580237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China), AuthorCompanyExt(id=1329869409465774542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869408509473218, companyId=1329869409453191628, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.中山大学药学院医药经济研究所,广东 广州 510006)])])]
冷家骅1, 2, 林子义3, 宣建伟3, *
作者信息
  • 1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142
  • 2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142
  • 3.中山大学药学院医药经济研究所,广东 广州 510006
通讯作者:
宣建伟,教授,研究方向:卫生政策、卫生经济学。
作者简介:

冷家骅,副主任医师,研究方向:医疗保险政策、肿瘤外科研究、卫生经济学。

Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China
Jiahua LENG1, 2, Ziyi LIN3, Jianwei XUAN3, *
Affiliations
  • 1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • 2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • 3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China
出版时间: 2023-01-10 doi: 10.13683/j.wph.2023.01.009
文章导航
收藏切换
目的

测算在2021年至2025年,对于我国程序性死亡受体配体1表达阳性(综合阳性评分≥10)的食管鳞癌患者二线治疗,帕博利珠单抗带来的潜在健康产出获益,以期为科学评估创新抗肿瘤药品临床获益,并有效配置卫生资源提供决策参考。

方法

建立流行病学测算模型,用于计算2021年至2025年可能使用帕博利珠单抗治疗的食管鳞癌患者二线治疗人数。再建立分区生存模型,预估平均1例患者使用帕博利珠单抗治疗对比常规化疗的生命年(life year,LY)和质量调整生命年(quality-adjusted life years,QALYs)增量获益。以5%年利率进行贴现,计算未来5年我国食管鳞癌患者二线治疗的总体潜在获益。

结果

预测未来5年,我国可能使用帕博利珠单抗的获益目标患者共43 439例,平均每例患者终身的LY和QALYs增量分别为1.603和1.442。帕博利珠单抗的引入给我国食管鳞癌患者二线治疗带来的5年总增量LY和QALYs,净现值分别为63 026 LY和56 696 QALYs。

结论

程序性死亡受体1抑制剂有望为中国食管鳞癌患者带来显著的生存和生命质量获益。

PD-1抑制剂  /  帕博利珠单抗  /  食管鳞癌  /  质量调整生命年
Objective

To estimate the potential health benefits of pembrolizumab for the second-line esophageal squamous cell carcinoma patients with programmed death-ligand 1 positive [combined positive score (CPS)≥10] in China from 2021 to 2025, in order to provide reference for scientific evaluation of clinical benefits of innovative antitumor drugs and effective allocation of health resources.

Methods

A patient flow calculation model and a partitioned survival model were built to calculate the number of patients with second-line esophageal squamous cell carcinoma who might be treated with pembrolizumab from 2021 to 2025. A partitioned survival model was established to estimate the incremental benefits of life year (LY) and quality-adjusted life years (QALYs) gained of an average patient using pembrolizumab compared with regular chemotherapies. The total potential gains in LY and QALYs of the second-line esophageal squamous cell carcinoma patients in China from 2021 to 2025 was calculated by discounting at 5% annually.

Results

In the next 5 years, a total of 43 439 patients could benefit from pembrolizumab. The average lifetime LY and QALYs increments per patient with pembrolizumab are 1.603 and 1.442, respectively. The total increments of LY and QALYs in 5 years gained by the introduction of pembrolizumab were 63 026 and 56 696, respectively.

Conclusions

Programmed death-1 inhibitor is expected to bring considerable survival and quality-of-life benefits for patients with esophageal squamous cell carcinoma in China.

PD-1 inhibitor  /  pembrolizumab  /  esophageal squamous cell carcinoma  /  quality-adjusted life year
冷家骅, 林子义, 宣建伟. PD-1抑制剂免疫治疗对中国食管鳞癌患者的潜在健康产出探索. 世界临床药物, 2023 , 44 (1) : 51 -58 . DOI: 10.13683/j.wph.2023.01.009
Jiahua LENG, Ziyi LIN, Jianwei XUAN. Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China[J]. World Clinical Drug, 2023 , 44 (1) : 51 -58 . DOI: 10.13683/j.wph.2023.01.009

参考文献 引证文献
排序方式:
[1]
国家卫生健康委员会. 食管癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192.
[2]
Wang Y, Shi J, Du L, et al. Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: a multicenter cross-sectional study[J]. Thoracic Cancer, 2020, 11(4): 1076-1089.
[3]
GBD 2017 Oesophageal Cancer Collaborators. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(6): 582-597.
[4]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南[M]. 北京: 人民卫生出版社, 2020.
[5]
Grünberger B, Raderer M, Schmidinger M, et al. Palliative chemotherapy for recurrent and metastatic esophageal cancer[J]. Anticancer Res, 2007, 27(4C): 2705-2714.
[6]
Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment[J]. J Thorac Dis, 2014, 6(Suppl 3): S289-S297.
[7]
国家药物和卫生技术综合评估中心(国家卫生健康委卫生发展研究中心). 国家药物和卫生技术综合评估中心关于发布心血管病、抗肿瘤、儿童药品临床综合评价技术指南的通知[EB/OL]. (2022-06-29) [2022-08-18]. http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f.shtml.
[8]
中国药学会. 中国药物经济学评价指南2020[EB/OL]. (2020-12-03) [2022-08-18]. https://www.cpa.org.cn/index.php?do=info&cid=75553.
[9]
Chen J, Luo S, Qin S, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the Chinese subgroup in KEYNOTE-181[J]. Annals Oncol, 2019, 30: v294.
[10]
孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11.
[11]
雷海科, 廖忠莉, 李小升, 等. 重庆市食管癌患者生存随访调查及预后影响因素研究[J]. 中国癌症杂志, 2020, 30(2): 98-105.
[12]
Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review[EB/OL]. (2017-06-02) [2022-08-18]. file:///C:/Users/shenjj/Downloads/TSD19-Partitioned-Survival-Analysis-final-report. pdf
[13]
Wang J, Chmielowski B, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naïve patients with advanced melanoma in the United States[J]. J Manag Care Spec Pharm, 2017, 23(2): 184-194.
[14]
Huang M, Lou Y, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States[J]. J Med Econ, 2017, 20(2): 140-150.
[15]
Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data[EB/OL]. (2013-03) [2022-08-18]. file:///C:/Users/shenjj/Downloads/TSD14-Survival-analysis. updated-March-2013. v2. pdf
[16]
Liu GG, Wu H, Li M, et al. Chinese time trade-off values for EQ-5D health states[J]. Value Health, 2014, 17(5): 597-604.
[17]
夏莉花, 濮晓红, 付尧, 等. 免疫组织化学、荧光原位杂交及RNA原位杂交检测PD-L1的一致性比较[J]. 中华病理学杂志, 2020, 49(11): 1183-1186.
[18]
骆新兰, 罗陆侨, 何娇, 等. 免疫组织化学检测条件对PD-L1(22C3)染色结果的影响[J]. 中华病理学杂志, 2020, 49(11): 1108-1113.
[19]
国家卫生健康委办公厅, 国家中医药局办公室, 中央军委后勤保障部卫生局. 关于印发肿瘤诊疗质量提升行动计划的通知[EB/OL]. (2021-10-15) [2022-08-18]. http://www.nhc.gov.cn/yzygj/s7659/202110/dea7d84638db44e28001fbd7d6c6801a.shtml.
[20]
中共中央国务院. “健康中国2030”规划纲要[EB/OL]. (2016-10-25) [2022-08-18]. http://www.gov.cn/xinwen/2016-10/25/content_5124174.htm.
[21]
Joung KI, Song JH, Suh K, et al. Effect of treatment with the PD-1/PD-L1 inhibitors on key health outcomes of cancer patients[J]. BioDrugs, 2021, 35(1): 61-73.
2023年第44卷第1期
11
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.01.009
  • 接收时间:2022-10-20
  • 首发时间:2026-11-18
  • 出版时间:2023-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-10-20
基金
作者信息
    1.北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心三病区,北京 100142
    2.北京大学肿瘤医院暨北京市肿瘤防治研究所医保处,北京 100142
    3.中山大学药学院医药经济研究所,广东 广州 510006

通讯作者:

宣建伟,教授,研究方向:卫生政策、卫生经济学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.01.009
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏